New research reveals increased rates of human papillomavirus infection and cervical cancer in women aged 65 years and older, highlighting the need to reconsider current screening guidelines.

A recent study found that unopposed estrogen therapy reduces young-onset breast cancer risk, while combined estrogen-progestin therapy increases it.

A major study of over 2 million women reveals that common pregnancy complications significantly increase the risk of stroke decades later.

A new study shows that a first-trimester blood test using cell-free RNA can predict early and late-onset preeclampsia with high accuracy.

A new study uncovers inherited epigenetic changes in embryos of women with polycystic ovary syndrome, offering insights into early risk detection and future fertility therapies.

A large-scale study finds women with endometriosis are 4 times more likely to conceive than those with other infertility diagnoses, offering new hope for patients.

A recent study highlighted a longer average pregnancy duration before abortion in states with bans, alongside increased travel time and costs.

A roundup of the most impactful FDA approvals in women’s health from January through June 2025, spanning diagnostics, therapeutics, and at-home care.

A panelist emphasizes that the OASIS 4 findings, with those of prior OASIS studies, strongly support the use of this drug class for managing vasomotor symptoms (VMS) in patients with breast cancer receiving endocrine therapy and highlights the need for future research in underserved populations such as men with breast cancer and those with metastatic disease.

A panelist explains that although liver function was closely monitored due to potential concerns about the investigational therapy and concurrent endocrine treatments, no serious hepatotoxicity was observed during the trial. However, continued monitoring in longer-term and real-world settings remains important to confirm the treatment’s liver safety profile.

A panelist notes that although the treatment was generally well tolerated—with fatigue, somnolence, and diarrhea being the most common adverse effects—long-term data on breast cancer outcomes such as recurrence and survival are still lacking, underscoring the need for extended follow-up and real-world evidence to fully assess long-term safety and efficacy.

New research reveals that reduced Parabacteroides merdae and elevated branched-chain amino acids in women with polycystic ovary syndrome may increase adverse pregnancy outcomes.

A look back at the most important FDA approvals, clinical research, and expert perspectives shaping ob-gyn care in the first half of 2025.

A new study reveals hybrid closed-loop technology significantly improves glucose control for pregnant women with T1D.

Eliminating a modest out-of-pocket cost significantly increased digital breast tomosynthesis use and reduced disparities across racial, ethnic, and language groups.

Take a quick look at everything you may have missed during Q2 of 2025, including the latest FDA approvals, top stories, and exclusive interviews.

Take a quick look at everything you may have missed last month, including the latest FDA updates and top stories.

A large European study finds that exposure to fine particulate matter during pregnancy may increase the risk of childhood overweight and obesity, especially in children aged 9 to 12 years.

Uterine fibroid care is evolving with more treatment options, fertility-focused planning, and a greater emphasis on quality of life and shared decision-making.

New research shows that analyzing sleep pattern variability from wearable devices can improve early prediction of preterm birth in pregnant women.

Experts warn that removing the COVID-19 vaccine from CDC guidelines endangers maternal and neonatal health and undermines evidence-based medical practice.

A new study finds women with postpartum hemorrhage face significantly higher odds of cardiovascular disease and thromboembolism for up to 15 years after childbirth.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

A panelist emphasizes that effectively managing endocrine therapy adverse effects—particularly vasomotor symptoms—can significantly improve treatment adherence, which is critical for reducing recurrence risk and improving survival in patients with breast cancer.

A panelist shares that secondary results from the trial showed early and sustained improvements in sleep and quality of life, underscoring the therapy’s potential to enhance endocrine treatment adherence by alleviating vasomotor symptoms (VMS) that often lead to poor adherence in patients with breast cancer.